What is Leerink Partnrs’ Forecast for TSBX Q1 Earnings?

Turnstone Biologics Corp. (NASDAQ:TSBX) – Equities research analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for Turnstone Biologics in a research report issued to clients and investors on Tuesday, April 1st. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings per share of ($0.13) for the quarter. The consensus estimate for Turnstone Biologics’ current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Turnstone Biologics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.13) EPS.

Turnstone Biologics (NASDAQ:TSBX) last released its earnings results on Friday, March 28th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.13.

Separately, Piper Sandler lowered Turnstone Biologics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $3.75 to $0.40 in a research note on Wednesday, February 5th.

Turnstone Biologics Trading Down 8.3 %

NASDAQ TSBX opened at $0.38 on Wednesday. The stock has a market cap of $8.70 million, a P/E ratio of -0.12 and a beta of 2.04. Turnstone Biologics has a 12-month low of $0.34 and a 12-month high of $3.88. The company has a fifty day simple moving average of $0.41 and a two-hundred day simple moving average of $0.47.

Hedge Funds Weigh In On Turnstone Biologics

An institutional investor recently bought a new position in Turnstone Biologics stock. Takeda Pharmaceutical Co. Ltd. bought a new position in shares of Turnstone Biologics Corp. (NASDAQ:TSBX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 895,824 shares of the company’s stock, valued at approximately $448,000. Turnstone Biologics comprises approximately 1.7% of Takeda Pharmaceutical Co. Ltd.’s investment portfolio, making the stock its 8th largest holding. Takeda Pharmaceutical Co. Ltd. owned approximately 3.87% of Turnstone Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). 52.51% of the stock is owned by hedge funds and other institutional investors.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.